Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 160: | Line 160: | ||
==Correlate them with their main outputs (Data. Narratives. Tools)== | ==Correlate them with their main outputs (Data. Narratives. Tools)== | ||
===Data=== | ===[[BGP Company Profiles - Data]]=== | ||
[http://www.nih.gov/ NIH] | [http://www.nih.gov/ NIH] | ||
Line 178: | Line 178: | ||
[http://www.biomedcentral.com/ BioMedCentral] | [http://www.biomedcentral.com/ BioMedCentral] | ||
===Tools= | ===[[BGP Company Profiles - Tools]]=== | ||
<br> | <br> | ||
Revision as of 17:13, 28 March 2009
What are the 10 biggest for-profit companies in this field?
Note on outputs: all these companies make their money primarily through developing and patenting drugs. The distinguishing factor seems to be that the largest of these companies produce the drugs themselves, while the smaller ones license these drugs to be produced by larger pharmaceutical companies
2006 Revenue ($m) | Headquarters | Primary Outputs | Instances of Commons-based approaches | |
Amgen | 14268
|
Thousand Oaks, California | ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline | Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed |
Genentech
|
9284
|
South San Francisco
|
synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process | ? |
Genzyme
|
3187
|
Cambridge, Massachusetts
|
Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue | ? |
Gilead Sciences
|
3026
|
Foster City, California | 11 commercial products
|
? |
Biogen Idec
|
2683
|
Cambridge, Massachusetts
|
Treatments for Crohn's disease, non-Hodgkin's lymphoma, and multiple sclerosis | Biogen outsources analyzing clinical trial data to other research labs (Powell pp. 72). Perhaps some of these exhibit commons-like behavior |
Cephalon
|
1764
|
Frazer, Pennsylvania | Specializes in treating neurodegenerative diseases | ? |
MedImmune
|
1277
|
Gaithersburg, Maryland | Only major drug prevents respiratory diseases in infants | ? |
Celgene
|
899
|
Summit, New Jersey
|
treatments for erythema nodosum leprosum ("ENL") and multiple myeloma | ? |
Abraxis BioScience
|
766
|
Los Angeles, California
|
uses patented nanoparticle technology to produce products for metastatic breast cancer | ? |
ImClone Systems
|
678
|
New York, New York
|
acquired by Eli Lilly, tried to produce Erbitux for Colorectal Cancer, but failed to win FDA approval | ? |
How is the market distributed?
Where are they located? Are there any incentives for specific locations?
Correlate them with their main outputs (Data. Narratives. Tools)
BGP Company Profiles - Data
BGP Company Profiles - Narratives
BGP Company Profiles - Tools
Bibliography for Item 6 in BGP
Biotechnology_-_Genomic_and_Proteomics